Alan Lamont
Queen Alexandra Hospital
6 Papers
112 Citations
Alan Lamont is an academic researcher from Queen Alexandra Hospital. The author has contributed to research in topics: Chemosensitivity assay & Chemotherapy. The author has an hindex of 6, co-authored 6 publications.
Chat about Author
Papers
Cancer cell adaptation to chemotherapy.
Federica Di Nicolantonio,Stuart Mercer,Louise A. Knight,Francis G Gabriel,Pauline A. Whitehouse,Sanjay Sharma,Augusta Fernando,Sharon Glaysher,Silvana Di Palma,Penny Johnson,Shaw Somers,Simon Toh,Bernard Higgins,Alan Lamont,Tim J. Gulliford,Jeremy Hurren,Constantinos Yiangou,Ian A. Cree +17 more
TL;DR: It is suggested that up-regulation of resistance genes or down-regulation in target genes may occur rapidly in human solid tumors, within days of the start of treatment, and that similar changes are present in pre- and post-chemotherapy biopsy material.
A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer
TL;DR: This small randomized clinical trial has documented a trend towards improved response and progression-free survival for assay-directed treatment for patients with platinum-resistant recurrent ovarian cancer, although a larger trial is required to confirm this.
97
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma.
Sanjay Sharma,Michael H Neale,Federica Di Nicolantonio,Louise A. Knight,Pauline A. Whitehouse,Stuart Mercer,Bernard Higgins,Alan Lamont,Richard H. Osborne,Andrew C Hindley,Christian M. Kurbacher,Ian A. Cree +11 more
TL;DR: The results show similar response rates to previous studies using ATP-TCA directed therapy in recurrent ovarian cancer, and the assay shows high evaluability and adds weight to the reproducibility of results from different centres.
The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian carcinoma.
TL;DR: Doxorubicin at concentrations achievable with liposomal preparations shows strong ex vivo activity against pre-treated recurrent ovarian cancer in just over half of the cases tested.
17
Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer.
Federica Di Nicolantonio,Michael H Neale,Louise A. Knight,Alan Lamont,Geraldine E Skailes,Richard J Osborne,Rosanne Allerton,Christian M. Kurbacher,Ian A. Cree +8 more
TL;DR: An ATP-based tumor chemosensitivity assay is used to determine the relative efficacy of high concentrations of doxorubicin tested in combination with cisplatin, treosulfan, 5-fluorouracil (5-FU) or vinorelbine against cells obtained from recurrent ovarian tumor tissue.
15